Opioid Approval Delay? Class REMS Poses Legal Questions For Pending Drugs

FDA approvability decisions on pending extended-release opioids will be contingent on the resolution of legal questions related to the agency's Risk Evaluation and Mitigation Strategy authorities under the FDA Amendments Act, Office of New Drug Director John Jenkins said